The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation

Table 2 Subgroup analysis for thromboembolic events comparing DOACs therapy with VKAs therapy

Category	Studies [references]	Patients	Pooled estimates		Test of heterogeneity
Category	Studies [references]	Patients	RR(95% CI)	p value	I²	p value
Sample size
≥ 1000	2 [15, 17]	3886	0.94 (0.72–1.22)	0.63	0%	0.97
< 1000	4 [16, 19,20,21]	1310	0.90 (0.42–1.92)	0.79	0%	0.45
Follow-up time
≥ 3 years	3 [16, 19, 20]	1049	1.07 (0.45–2.55)	0.88	0%	0.37
< 3 years	3 [15, 17, 21]	4147	0.92 (0.71–1.19)	0.54	0%	0.76
Population
Western	2 [15, 16]	1959	0.74 (0.29–1.87)	0.52	0%	0.37
East Asian	4 [17, 19,20,21]	3237	0.95 (0.74–1.23)	0.70	0%	0.67
Analysis model
Fixed effect	6 [15,16,17, 19,20,21]	5196	0.93 (0.73–1.20)	0.59	0%	0.75
Random effect	6 [15,16,17, 19,20,21]	5196	0.93 (0.73–1.20)	0.59	0%	0.75

Abbreviations: DOACs direct oral anticoagulants, VKAs vitamin K antagonists, RR odd ratio, CI confidence interval

ISSN: 1477-9560